2023 World Conference on Lung Cancer (Posters)-P2.10. Cost of Managing Brain Metastases in Patients with ALK+ aNSCLC with First-Line Tyrosine Kinase Inhibitors (TKIs) in the UK

P2.10. Cost of Managing Brain Metastases in Patients with ALK+ aNSCLC with First-Line Tyrosine Kinase Inhibitors (TKIs) in the UK - PDF(Slides)

Back to course

Pdf Summary

This study aimed to estimate the annual costs of managing brain metastases (BM) in patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) receiving first-line tyrosine kinase inhibitors (TKIs) in the UK. The study found a direct relationship between a lower cumulative incidence of progression of BM and lower cost burden in patients with ALK-positive advanced NSCLC receiving TKIs. Specifically, the 12-month and 24-month cumulative incidence of progression of BM was lower in patients receiving lorlatinib compared to crizotinib and alectinib. This resulted in lower management costs per patient-year for lorlatinib compared to the other two TKIs. The study used resource consumption and unit cost data from the UK National Health Service to estimate the annual costs of managing patients with ALK-positive NSCLC with or without BM. The costs included medical visits, hospitalizations, laboratory tests, imaging, and surgical procedures. The study also considered the costs of treatment-emergent adverse events (AEs) in a scenario analysis. The results showed that lorlatinib had cost savings compared to crizotinib and alectinib in all populations studied when considering both the base case and the scenario including AE costs. Overall, this study provides insights into the cost of managing BM in patients with ALK-positive advanced NSCLC receiving first-line TKIs in the UK and highlights the potential cost savings associated with specific TKIs.

Asset Subtitle

Hannah Le

Meta Tag

Speaker Hannah Le

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

brain metastases

anaplastic lymphoma kinase

ALK-positive advanced NSCLC

tyrosine kinase inhibitors

lorlatinib

crizotinib

alectinib

cost burden

medical visits

treatment-emergent adverse events